O	0	4	T140	T140	CD	B-NP
O	5	12	analogs	analog	NNS	I-NP
O	13	15	as	as	IN	B-PP
O	16	21	CXCR4	CXCR4	NN	B-NP
O	22	33	antagonists	antagonist	NNS	I-NP
O	34	44	identified	identify	VBN	B-VP
O	45	47	as	as	IN	B-PP
O	48	52	anti	anti	AFX	B-NP
O	52	53	-	-	HYPH	I-NP
O	53	63	metastatic	metastatic	JJ	I-NP
O	64	70	agents	agent	NNS	I-NP
O	71	73	in	in	IN	B-PP
O	74	77	the	the	DT	B-NP
O	78	87	treatment	treatment	NN	I-NP
O	88	90	of	of	IN	B-PP
B-Cancer	91	97	breast	breast	NN	B-NP
I-Cancer	98	104	cancer	cancer	NN	I-NP
O	104	105	.	.	.	O

O	107	108	A	A	DT	B-NP
O	109	118	chemokine	chemokine	NN	I-NP
O	119	127	receptor	receptor	NN	I-NP
O	127	128	,	,	,	O
O	129	134	CXCR4	CXCR4	NN	B-NP
O	134	135	,	,	,	O
O	136	139	and	and	CC	O
O	140	143	its	its	PRP$	B-NP
O	144	154	endogenous	endogenous	JJ	I-NP
O	155	161	ligand	ligand	NN	I-NP
O	161	162	,	,	,	O
O	163	170	stromal	stromal	JJ	B-NP
O	171	175	cell	cell	NN	I-NP
O	175	176	-	-	HYPH	O
O	176	183	derived	derive	VBN	B-NP
O	184	190	factor	factor	NN	I-NP
O	190	191	-	-	HYPH	O
O	191	192	1	1	CD	B-NP
O	193	194	(	(	(	O
O	194	197	SDF	SDF	NN	B-NP
O	197	198	-	-	HYPH	B-NP
O	198	199	1	1	CD	I-NP
O	199	200	)	)	)	O
O	200	201	,	,	,	O
O	202	206	have	have	VBP	B-VP
O	207	211	been	be	VBN	I-VP
O	212	222	recognized	recognize	VBN	I-VP
O	223	225	to	to	TO	I-VP
O	226	228	be	be	VB	I-VP
O	229	237	involved	involve	VBN	I-VP
O	238	240	in	in	IN	B-PP
O	241	244	the	the	DT	B-NP
O	245	255	metastasis	metastasis	NN	I-NP
O	256	258	of	of	IN	B-PP
O	259	266	several	several	JJ	B-NP
O	267	272	types	type	NNS	I-NP
O	273	275	of	of	IN	B-PP
B-Cancer	276	283	cancers	cancer	NNS	B-NP
O	283	284	.	.	.	O

O	285	289	T140	T140	NN	B-NP
O	290	297	analogs	analog	NNS	I-NP
O	298	301	are	be	VBP	B-VP
O	302	310	peptidic	peptidic	JJ	B-NP
O	311	316	CXCR4	CXCR4	NN	I-NP
O	317	328	antagonists	antagonist	NNS	I-NP
O	329	337	composed	compose	VBN	B-VP
O	338	340	of	of	IN	B-PP
O	341	343	14	14	CD	B-NP
O	344	349	amino	amino	NN	I-NP
O	350	354	acid	acid	NN	I-NP
O	355	363	residues	residue	NNS	I-NP
O	364	368	that	that	WDT	B-NP
O	369	373	were	be	VBD	B-VP
O	374	384	previously	previously	RB	I-VP
O	385	394	developed	develop	VBN	I-VP
O	395	397	as	as	IN	B-PP
O	398	402	anti	anti	AFX	B-NP
O	402	403	-	-	HYPH	I-NP
O	403	406	HIV	HIV	NN	I-NP
O	407	413	agents	agent	NNS	I-NP
O	414	420	having	have	VBG	B-VP
O	421	431	inhibitory	inhibitory	JJ	B-NP
O	432	440	activity	activity	NN	I-NP
O	441	448	against	against	IN	B-PP
O	449	452	HIV	HIV	NN	B-NP
O	452	453	-	-	HYPH	B-NP
O	453	458	entry	entry	NN	I-NP
O	459	466	through	through	IN	B-PP
O	467	470	its	its	PRP$	B-NP
O	471	473	co	co	AFX	I-NP
O	473	474	-	-	HYPH	I-NP
O	474	482	receptor	receptor	NN	I-NP
O	482	483	,	,	,	O
O	484	489	CXCR4	CXCR4	NN	B-NP
O	489	490	.	.	.	O

O	491	497	Herein	Herein	RB	B-ADVP
O	497	498	,	,	,	O
O	499	501	we	we	PRP	B-NP
O	502	508	report	report	VBP	B-VP
O	509	513	that	that	IN	B-SBAR
O	514	519	these	these	DT	B-NP
O	520	529	compounds	compound	NNS	I-NP
O	530	541	effectively	effectively	RB	B-ADVP
O	542	551	inhibited	inhibit	VBD	B-VP
O	552	555	SDF	SDF	NN	B-NP
O	555	556	-	-	HYPH	B-NP
O	556	557	1	1	CD	I-NP
O	557	558	-	-	HYPH	B-NP
O	558	565	induced	induce	VBN	I-NP
O	566	575	migration	migration	NN	I-NP
O	576	578	of	of	IN	B-PP
O	579	584	human	human	JJ	B-NP
B-Cell	585	591	breast	breast	NN	I-NP
I-Cell	592	598	cancer	cancer	NN	I-NP
I-Cell	599	604	cells	cell	NNS	I-NP
O	605	606	(	(	(	O
B-Cell	606	609	MDA	MDA	NN	B-NP
I-Cell	609	610	-	-	HYPH	B-NP
I-Cell	610	612	MB	MB	NN	I-NP
I-Cell	612	613	-	-	HYPH	B-NP
I-Cell	613	616	231	231	CD	I-NP
O	616	617	)	)	)	O
O	617	618	,	,	,	O
O	619	624	human	human	JJ	B-NP
B-Cell	625	633	leukemia	leukemia	NN	I-NP
I-Cell	634	635	T	T	NN	I-NP
I-Cell	636	641	cells	cell	NNS	I-NP
O	642	643	(	(	(	O
B-Cell	643	646	Sup	Sup	NN	B-NP
I-Cell	646	647	-	-	HYPH	B-NP
I-Cell	647	649	T1	T1	NN	I-NP
O	649	650	)	)	)	O
O	651	654	and	and	CC	O
B-Cell	655	660	human	human	JJ	B-NP
I-Cell	661	670	umbilical	umbilical	JJ	I-NP
I-Cell	671	675	vein	vein	NN	I-NP
I-Cell	676	687	endothelial	endothelial	JJ	I-NP
I-Cell	688	693	cells	cell	NNS	I-NP
O	694	696	at	at	IN	B-PP
O	697	711	concentrations	concentration	NNS	B-NP
O	712	714	of	of	IN	B-PP
O	715	717	10	10	CD	B-NP
O	717	718	-	-	HYPH	I-NP
O	718	721	100	100	CD	I-NP
O	722	724	nM	nM	NN	I-NP
O	725	727	in	in	FW	B-ADVP
O	728	733	vitro	vitro	FW	I-ADVP
O	733	734	.	.	.	O

O	735	746	Furthermore	Furthermore	RB	B-ADVP
O	746	747	,	,	,	O
O	748	752	slow	slow	JJ	B-NP
O	753	760	release	release	NN	I-NP
O	761	775	administration	administration	NN	I-NP
O	776	778	by	by	IN	B-PP
B-Immaterial_anatomical_entity	779	791	subcutaneous	subcutaneous	JJ	B-NP
O	792	801	injection	injection	NN	I-NP
O	802	807	using	use	VBG	B-VP
O	808	810	an	an	DT	B-NP
O	811	816	Alzet	Alzet	NNP	I-NP
O	817	824	osmotic	osmotic	JJ	I-NP
O	825	829	pump	pump	NN	I-NP
O	830	832	of	of	IN	B-PP
O	833	834	a	a	DT	B-NP
O	835	841	potent	potent	JJ	I-NP
O	842	845	and	and	CC	I-NP
O	846	849	bio	bio	AFX	I-NP
O	849	850	-	-	HYPH	I-NP
O	850	856	stable	stable	JJ	I-NP
O	857	861	T140	T140	NN	I-NP
O	862	868	analog	analog	NN	I-NP
O	868	869	,	,	,	O
O	870	872	4F	4F	NN	B-NP
O	872	873	-	-	HYPH	B-NP
O	873	880	benzoyl	benzoyl	NN	I-NP
O	880	881	-	-	HYPH	B-NP
O	881	888	TN14003	TN14003	NN	I-NP
O	888	889	,	,	,	O
O	890	894	gave	give	VBD	B-VP
O	895	896	a	a	DT	B-NP
O	897	904	partial	partial	JJ	I-NP
O	904	905	,	,	,	O
O	906	909	but	but	CC	O
O	910	923	statistically	statistically	RB	B-ADJP
O	924	935	significant	significant	JJ	I-ADJP
O	936	937	(	(	(	O
O	937	938	P	P	NN	B-NP
O	938	939	<	<	SYM	O
O	939	940	/	/	SYM	B-NP
O	940	941	=	=	SYM	B-VP
O	941	942	0	0	CD	B-NP
O	942	943	.	.	SYM	I-NP
O	943	945	05	05	CD	I-NP
O	946	947	(	(	(	O
O	947	948	t	t	NN	B-NP
O	948	949	-	-	HYPH	O
O	949	953	test	test	NN	B-NP
O	953	954	)	)	)	O
O	954	955	)	)	)	O
O	956	965	reduction	reduction	NN	B-NP
O	966	968	in	in	IN	B-PP
B-Organ	969	978	pulmonary	pulmonary	JJ	B-NP
O	979	989	metastasis	metastasis	NN	I-NP
O	990	992	of	of	IN	B-PP
B-Cell	993	996	MDA	MDA	NN	B-NP
I-Cell	996	997	-	-	HYPH	B-NP
I-Cell	997	999	MB	MB	NN	I-NP
I-Cell	999	1000	-	-	HYPH	O
I-Cell	1000	1003	231	231	CD	B-NP
O	1004	1006	in	in	IN	B-PP
O	1007	1011	SCID	SCID	NN	B-NP
O	1012	1016	mice	mouse	NNS	I-NP
O	1016	1017	,	,	,	O
O	1018	1022	even	even	RB	B-SBAR
O	1023	1029	though	though	IN	I-SBAR
O	1030	1032	no	no	DT	B-NP
O	1033	1040	attempt	attempt	NN	I-NP
O	1041	1044	was	be	VBD	B-VP
O	1045	1049	made	make	VBN	I-VP
O	1050	1052	to	to	TO	B-VP
O	1053	1060	inhibit	inhibit	VB	I-VP
O	1061	1066	other	other	JJ	B-NP
O	1067	1076	important	important	JJ	I-NP
O	1077	1084	targets	target	NNS	I-NP
O	1085	1089	such	such	JJ	B-PP
O	1090	1092	as	as	IN	I-PP
O	1093	1097	CCR7	CCR7	NN	B-NP
O	1097	1098	.	.	.	O

O	1099	1104	These	These	DT	B-NP
O	1105	1112	results	result	NNS	I-NP
O	1113	1120	suggest	suggest	VBP	B-VP
O	1121	1125	that	that	IN	B-SBAR
O	1126	1130	T140	T140	NN	B-NP
O	1131	1138	analogs	analog	NNS	I-NP
O	1139	1143	have	have	VBP	B-VP
O	1144	1153	potential	potential	JJ	B-NP
O	1154	1157	use	use	NN	I-NP
O	1158	1161	for	for	IN	B-PP
B-Cancer	1162	1168	cancer	cancer	NN	B-NP
O	1169	1176	therapy	therapy	NN	I-NP
O	1176	1177	,	,	,	O
O	1178	1181	and	and	CC	O
O	1182	1186	that	that	IN	B-SBAR
O	1187	1192	small	small	JJ	B-NP
O	1193	1202	molecular	molecular	JJ	I-NP
O	1203	1208	CXCR4	CXCR4	NN	I-NP
O	1209	1220	antagonists	antagonist	NNS	I-NP
O	1221	1226	could	could	MD	B-VP
O	1227	1238	potentially	potentially	RB	I-VP
O	1239	1246	replace	replace	VB	I-VP
O	1247	1259	neutralizing	neutralize	VBG	B-NP
O	1260	1270	antibodies	antibody	NNS	I-NP
O	1271	1273	as	as	IN	B-PP
O	1274	1278	anti	anti	AFX	B-NP
O	1278	1279	-	-	HYPH	I-NP
O	1279	1289	metastatic	metastatic	JJ	I-NP
O	1290	1296	agents	agent	NNS	I-NP
O	1297	1300	for	for	IN	B-PP
B-Cancer	1301	1307	breast	breast	NN	B-NP
I-Cancer	1308	1314	cancer	cancer	NN	I-NP
O	1314	1315	.	.	.	O

